Abata Therapeutics
Samantha Singer, MS, MBA - President & CEO
Richard Ransohoff, M.D. - Co-Founder & Interim Chief Medical Officer
Series A
Lightspeed Team
Dr. Shelley Chu - Partner

Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases. Founded by pioneers in Treg biology, T cell receptor, and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable. In addition to its lead program in progressive MS, Abata has programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM) – also tissue-specific autoimmune diseases with substantial unmet need and a strong rationale for Abata’s Treg approach. The company was launched in 2021 by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital, and the JDRF T1D Fund. Abata is based in Cambridge, Mass. For more information, please visit abatatx.com or follow us on Twitter or LinkedIn.

Dr. Shelley Chu